Fulgent Genetics (FLGT) director receives stock units and 8,426-share option grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Fulgent Genetics director Michael Nohaile reported new equity awards. He received 5,558 shares of common stock as a grant, bringing his direct holdings to 24,578 shares. He was also granted options on 8,426 shares at an exercise price of $16.19 per share, expiring on May 13, 2036.
The 5,558 restricted stock units and the 8,426 options both vest over four years. One quarter vest 12 months after May 14, 2026, and the remainder vest in equal quarterly installments over the following 36 months, contingent on continued service with the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Nohaile Michael
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 8,426 | $0.00 | -- |
| Grant/Award | Common Stock | 5,558 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 8,426 shares (Direct, null);
Common Stock — 24,578 shares (Direct, null)
Footnotes (1)
- Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after May 14, 2026, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date. The shares subject to the option vest over a period of four years, with 1/4th of such shares vesting 12 months after May 14, 2026, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to the reporting person's continued service for Issuer on each vesting date.
Key Figures
Restricted stock units granted: 5,558 shares
Options granted: 8,426 options
Option exercise price: $16.19 per share
+3 more
6 metrics
Restricted stock units granted
5,558 shares
Common Stock grant on May 14, 2026
Options granted
8,426 options
Stock Option (Right to Buy) on May 14, 2026
Option exercise price
$16.19 per share
Conversion or exercise price for 8,426-share option grant
Option expiration
May 13, 2036
Expiration date of Stock Option (Right to Buy)
Shares owned after grant
24,578 shares
Total common stock directly held following transaction
Vesting schedule duration
4 years
Vesting period for RSUs and options from May 14, 2026
Key Terms
Restricted stock units, Stock Option (Right to Buy), exercise price, vesting
4 terms
Restricted stock units financial
"Restricted stock units. The shares subject to the restricted stock units vest over a period of four years"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) ... The shares subject to the option vest over a period of four years"
exercise price financial
"conversion_or_exercise_price: "16.1900""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"1/4th of such shares vesting 12 months after May 14, 2026, and 1/16th of such shares vesting at the end of every three month period"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What insider transaction did Fulgent Genetics (FLGT) disclose for Michael Nohaile?
Fulgent Genetics disclosed that director Michael Nohaile received equity awards: 5,558 shares of common stock and options on 8,426 shares. These awards are compensation-related grants, not open-market purchases or sales, and are subject to time-based vesting conditions tied to his continued service.
What are the terms of Michael Nohaile’s stock option grant at Fulgent Genetics (FLGT)?
Michael Nohaile received options on 8,426 Fulgent Genetics shares with a $16.19 exercise price, expiring May 13, 2036. The options vest over four years, starting 12 months after May 14, 2026, then in equal quarterly installments, conditional on continued service with the company.
How do the restricted stock units granted to Michael Nohaile at Fulgent Genetics (FLGT) vest?
The 5,558 restricted stock units vest over four years. One quarter vests 12 months after May 14, 2026, and the remaining three quarters vest in equal installments at the end of each three-month period over the next 36 months, subject to his continued service.
Are Michael Nohaile’s recent Fulgent Genetics (FLGT) equity awards open-market buys or compensation grants?
The Form 4 classifies both awards as grants or awards, not open-market transactions. Nohaile received 5,558 shares of common stock and options on 8,426 shares as compensation, with a reported price per share of $0.00, subject to standard multi-year vesting requirements.